Table of Contents
- What is IMM-101?
- How Does IMM-101 Work?
- Potential Uses of IMM-101
- Current Clinical Trials
- How is IMM-101 Administered?
- Possible Side Effects
- Who Might Be Eligible for IMM-101 Treatment?
What is IMM-101?
IMM-101 is an innovative immunotherapy drug that is currently being studied for its potential in treating various types of cancer. The active ingredient in IMM-101 is heat-killed Mycobacterium obuense, a type of bacteria that has been specially prepared to stimulate the immune system[1]. This medication is also known by its full scientific name: Mycobacterium obuense, strain NCTC 13365, heat-killed.
How Does IMM-101 Work?
IMM-101 works by stimulating the body’s immune system. When introduced into the body, it helps activate certain immune cells, potentially enhancing the body’s natural ability to fight cancer. This approach is part of a broader category of treatments called immunostimulants, which aim to boost the immune system’s response against diseases like cancer[1].
Potential Uses of IMM-101
While research is ongoing, IMM-101 is being studied for its potential in treating several types of cancer, including:
- Pancreatic cancer: Particularly in patients with limited metastatic pancreatic cancer[1].
- Colorectal cancer: Specifically in patients with certain genetic characteristics (MSI-high or MMR-deficient) and at specific stages of the disease[2].
It’s important to note that IMM-101 is still considered an experimental treatment and is not yet approved for general use outside of clinical trials.
Current Clinical Trials
IMM-101 is currently being studied in several clinical trials:
MEPANC-1 Trial: This study is investigating the safety and effectiveness of IMM-101 combined with stereotactic radiotherapy in patients with limited metastatic pancreatic cancer. The trial aims to determine if this combination can improve progression-free survival[1].
ANTONIO Trial: This study is looking at the use of IMM-101 in combination with another immunotherapy drug called atezolizumab for patients with colorectal cancer. The trial is specifically for patients who can’t receive or refuse standard chemotherapy with oxaliplatin[2].
How is IMM-101 Administered?
IMM-101 is given as an intradermal injection. This means it’s injected just under the skin, rather than into a muscle or vein. The medication comes in the form of a suspension, which is a liquid containing small particles of the drug[1][2].
Possible Side Effects
As with any medical treatment, IMM-101 may cause side effects. However, because it’s still in the clinical trial phase, the full range of potential side effects is not yet known. The ongoing trials are designed to assess the safety and tolerability of IMM-101, which will provide more information about possible side effects[1][2].
Who Might Be Eligible for IMM-101 Treatment?
Eligibility for IMM-101 treatment in clinical trials varies depending on the specific study. However, some general criteria may include:
- Being 18 years of age or older
- Having a confirmed diagnosis of the specific type of cancer being studied (e.g., pancreatic cancer or colorectal cancer)
- Having cancer at a specific stage or with specific genetic characteristics
- Being ineligible for or having refused standard treatments
- Having adequate organ function and overall health status
It’s important to note that there are also several conditions that might make a person ineligible for IMM-101 treatment in these trials, such as certain autoimmune diseases, active infections, or previous treatment with similar immunotherapies[1][2].
If you’re interested in learning more about IMM-101 or participating in a clinical trial, it’s crucial to discuss this with your healthcare provider. They can provide more information and help determine if this experimental treatment might be appropriate for your specific situation.
